Baili Tianheng announced that Yizekang is used for unresectable or metastatic HR+HER2- breast cancer that has received endocrine treatment in the past and has received at least first-line chemotherapy in advanced stages of the disease. The company recently received the CDE “Notice of Acceptance”. The application for marketing of the drug has been officially accepted; the application was based on the analysis results of the phase III clinical trial, and the trial reached the main end of the progression-free survival period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.